Results 11 to 20 of about 908,037 (360)

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

open access: yesJournal of the American Medical Association (JAMA), 2021
Importance The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or obesity is unknown.
D. Rubino   +13 more
semanticscholar   +1 more source

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.

open access: yesJournal of the American Medical Association (JAMA), 2021
Importance Weight loss improves cardiometabolic risk factors in people with overweight or obesity. Intensive lifestyle intervention and pharmacotherapy are the most effective noninvasive weight loss approaches.
T. Wadden   +12 more
semanticscholar   +1 more source

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

open access: yesNew England Journal of Medicine, 2020
BACKGROUND Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited.
P. Newsome   +8 more
semanticscholar   +1 more source

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

open access: yesJournal of Clinical Oncology, 2020
PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small ...
S. Gadgeel   +25 more
semanticscholar   +1 more source

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

open access: yesJournal of Clinical Oncology, 2020
PURPOSE Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus etoposide and platinum (EP) with placebo plus EP for ...
C. Rudin   +20 more
semanticscholar   +1 more source

PLACEBOES. [PDF]

open access: yesJournal of the American Medical Association, 1885
n ...
openaire   +2 more sources

Placebo Effect in the Treatment of Depression and Anxiety

open access: yesFrontiers in Psychiatry, 2019
The aim of this review is to evaluate the placebo effect in the treatment of anxiety and depression. Antidepressants are supposed to work by fixing a chemical imbalance, specifically, a lack of serotonin or norepinephrine in the brain.
Irving Kirsch
doaj   +1 more source

Lack of Effects of the Presence of a Dog on Pain Perception in Healthy Participants—A Randomized Controlled Trial

open access: yesFrontiers in Pain Research, 2021
Animal-assisted interventions (AAIs) have been shown to be effective in the treatment of pain. Studies suggest that relationships with animals can have comparable qualities to relationships with humans and that this enables animals to provide social ...
Cora Wagner   +8 more
doaj   +1 more source

PLACEBOES [PDF]

open access: yesSouthern Medical Journal, 1916
n ...
openaire   +1 more source

Error-related negativity and the misattribution of state-anxiety following errors: On the reproducibility of Inzlicht and Al-Khindi (2012)

open access: yesFrontiers in Human Neuroscience, 2016
In their innovative study, Inzlicht and Al-Khindi (2012) demonstrated that participants who were allowed to misattribute their arousal and negative affect induced by errors to a placebo beverage had a reduced error-related negativity (ERN/Ne) compared to
Carmen Cano Rodilla   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy